Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 37.2
(-2.11%)
SEK 37.2
(-2.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -131.93 Million SEK | -144.13% |
| 2022 | -54.22 Million SEK | -5.93% |
| 2021 | -51.18 Million SEK | -134.24% |
| 2020 | -21.85 Million SEK | -212.0% |
| 2019 | 19.51 Million SEK | 262.05% |
| 2018 | -12.04 Million SEK | -1968.73% |
| 2017 | -582 Thousand SEK | 96.81% |
| 2016 | -18.26 Million SEK | -44.23% |
| 2015 | -12.66 Million SEK | 35.99% |
| 2014 | -19.78 Million SEK | -277.33% |
| 2013 | 11.15 Million SEK | 34.56% |
| 2012 | 8.29 Million SEK | 158.86% |
| 2011 | -14.08 Million SEK | 62.21% |
| 2010 | -37.28 Million SEK | -1056.79% |
| 2009 | 3.89 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -1.94 Million SEK | 85.11% |
| 2024 Q1 | -17.01 Million SEK | 33.95% |
| 2024 Q2 | -13.04 Million SEK | 23.32% |
| 2023 Q4 | -25.75 Million SEK | -19.28% |
| 2023 FY | -132.38 Million SEK | -144.13% |
| 2023 Q1 | -18.7 Million SEK | 14.06% |
| 2023 Q2 | -67.84 Million SEK | -262.69% |
| 2023 Q3 | -21.59 Million SEK | 68.17% |
| 2022 Q3 | -5.94 Million SEK | 35.69% |
| 2022 Q4 | -21.76 Million SEK | -266.26% |
| 2022 FY | -54.22 Million SEK | -5.93% |
| 2022 Q1 | -16.56 Million SEK | 30.44% |
| 2022 Q2 | -9.24 Million SEK | 44.22% |
| 2021 Q1 | -9.7 Million SEK | -50.82% |
| 2021 Q3 | -10.67 Million SEK | -6.83% |
| 2021 Q4 | -23.81 Million SEK | -123.17% |
| 2021 FY | -51.18 Million SEK | -134.24% |
| 2021 Q2 | -9.99 Million SEK | -2.95% |
| 2020 Q2 | -777 Thousand SEK | -120.1% |
| 2020 Q1 | 3.86 Million SEK | 122.25% |
| 2020 FY | -21.85 Million SEK | -212.0% |
| 2020 Q3 | -14.29 Million SEK | -1739.25% |
| 2020 Q4 | -6.43 Million SEK | 54.97% |
| 2019 FY | 19.51 Million SEK | 262.05% |
| 2019 Q4 | 1.73 Million SEK | -93.29% |
| 2019 Q3 | 25.9 Million SEK | 641.44% |
| 2019 Q2 | -4.78 Million SEK | -41.48% |
| 2019 Q1 | -3.38 Million SEK | 33.85% |
| 2018 Q3 | -167 Thousand SEK | -235.77% |
| 2018 Q4 | -5.11 Million SEK | -2961.68% |
| 2018 FY | -12.04 Million SEK | -1968.73% |
| 2018 Q1 | -6.88 Million SEK | -8103.49% |
| 2018 Q2 | 123 Thousand SEK | 101.79% |
| 2017 Q4 | 86 Thousand SEK | 131.97% |
| 2017 Q3 | -269 Thousand SEK | 94.35% |
| 2017 FY | -582 Thousand SEK | 96.81% |
| 2017 Q2 | -4.76 Million SEK | -209.14% |
| 2017 Q1 | 4.36 Million SEK | 211.72% |
| 2016 Q3 | 1.43 Million SEK | 124.25% |
| 2016 Q4 | -3.9 Million SEK | -372.33% |
| 2016 Q1 | -9.87 Million SEK | -166.91% |
| 2016 FY | -18.26 Million SEK | -44.23% |
| 2016 Q2 | -5.91 Million SEK | 40.07% |
| 2015 Q3 | 25.66 Million SEK | 241.26% |
| 2015 Q1 | -34.92 Million SEK | -200.24% |
| 2015 FY | -12.66 Million SEK | 35.99% |
| 2015 Q2 | -18.16 Million SEK | 47.98% |
| 2015 Q4 | 14.75 Million SEK | -42.49% |
| 2014 Q2 | -5.23 Million SEK | -317.58% |
| 2014 Q4 | -11.63 Million SEK | -118.3% |
| 2014 FY | -19.78 Million SEK | -277.33% |
| 2014 Q3 | -5.32 Million SEK | -1.78% |
| 2014 Q1 | 2.4 Million SEK | -86.33% |
| 2013 Q3 | -2.89 Million SEK | 4.49% |
| 2013 Q4 | 17.6 Million SEK | 708.75% |
| 2013 Q1 | -525 Thousand SEK | -118.53% |
| 2013 Q2 | -3.02 Million SEK | -476.76% |
| 2013 FY | 11.15 Million SEK | 34.56% |
| 2012 Q2 | -7.96 Million SEK | 0.0% |
| 2012 FY | 8.29 Million SEK | 158.86% |
| 2012 Q4 | 2.83 Million SEK | 146.06% |
| 2012 Q3 | -6.15 Million SEK | 22.72% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | -14.08 Million SEK | 62.21% |
| 2010 FY | -37.28 Million SEK | -1056.79% |
| 2009 FY | 3.89 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | -70.12% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 143.89% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 143.89% |
| Arcoma AB | 4.66 Million SEK | 2931.18% |
| BICO Group AB (publ) | -618.3 Million SEK | 78.662% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 435.964% |
| CellaVision AB (publ) | 167.05 Million SEK | 178.978% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | -100.102% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -346.148% |
| C-Rad AB (publ) | 44.24 Million SEK | 398.194% |
| Duearity AB (publ) | -25.76 Million SEK | -412.103% |
| Dignitana AB (publ) | -15.02 Million SEK | -778.031% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -39.17% |
| Getinge AB (publ) | 3.81 Billion SEK | 103.459% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | -92.755% |
| Iconovo AB (publ) | -45.77 Million SEK | -188.21% |
| Integrum AB (publ) | 6.51 Million SEK | 2125.892% |
| Luxbright AB (publ) | -25.8 Million SEK | -411.28% |
| Mentice AB (publ) | -679 Thousand SEK | -19330.486% |
| OssDsign AB (publ) | -91.95 Million SEK | -43.474% |
| Paxman AB (publ) | 12.61 Million SEK | 1145.511% |
| Promimic AB (publ) | -9.11 Million SEK | -1346.951% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 21.793% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -144.597% |
| ScandiDos AB (publ) | -13.48 Million SEK | -878.514% |
| Sectra AB (publ) | 518.49 Million SEK | 125.446% |
| Sedana Medical AB (publ) | -65.54 Million SEK | -101.28% |
| Senzime AB (publ) | -133.74 Million SEK | 1.355% |
| SpectraCure AB (publ) | -21.35 Million SEK | -517.924% |
| Stille AB | 44.95 Million SEK | 393.498% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 96.324% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 442.63% |